Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionLegal & General Group Plc
Latest Disclosed Ownership451,056 shares
Latest Disclosed Value $ 13,400,874
Legal & General Group Plc reports 15.99% decrease in ownership of TVTX / Travere Therapeutics, Inc.

On May 8, 2026 - Legal & General Group Plc filed a 13F-HR form disclosing ownership of 451,056 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $13,400,874 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 9, 2026 disclosing 536,925 shares of Travere Therapeutics, Inc.. This represents a change in shares of -15.99% during the quarter. The current value of the position is $20,387,731 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 451,056 -85,869 -15.99 13,401 -34.68 0.0031
2026-02-09 2025-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 536,925 16,333 3.14 20,516 64.89 0.0045
2025-11-13 2025-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 520,592 10,164 1.99 12,442 64.71 0.0028
2025-08-12 2025-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 510,428 97,496 23.61 7,554 2.09 0.0019
2025-05-15 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 412,932 333,969 422.94 7,400 438.11 0.0020
2025-02-13 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 78,963 -1,995 -2.46 1,376 21.47 0.0004
2025-02-28 2024-09-30 13F/A-2 TRAVERE THERAPEUTICS COM 89422G107 80,958 6,718 9.05 1,133 85.57 0.0003
2024-11-14 2024-09-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 90,972 12,996 1,273 0.0003
2024-11-14 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 90,972 12,996 1,273 0.0001
2025-05-29 2024-06-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 74,240 -913 -1.21 610 5.35 0.0002
2024-08-14 2024-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 77,976 2,823 641 0.0001
2025-05-29 2024-03-31 13F/A-2 TRAVERE THERAPEUTICS COM 89422G107 75,153 -59,699 -44.27 579 -52.23 0.0002
2024-07-01 2024-03-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 75,153 -59,699 579 0.0001
2024-05-14 2024-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 75,153 -59,699 579 0.0001
2025-05-29 2023-12-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 134,852 -37,090 -21.57 1,212 -21.15 0.0004
2024-02-15 2023-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 134,852 -37,090 1,212 0.0003
2023-11-14 2023-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 171,942 36,404 26.86 1,537 -26.14 0.0005
2023-08-14 2023-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 135,538 10,306 8.23 2,082 -26.10 0.0007
2023-05-15 2023-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 125,232 49,939 66.33 2,816 77.89 0.0010
2023-02-14 2022-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 75,293 11,211 17.49 1,583 0.25 0.0006
2022-11-14 2022-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 64,082 41,481 183.54 1,579 188.14 0.0006
2022-08-22 2022-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 22,601 957 4.42 548 -1.79 0.0002
2022-05-16 2022-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 21,644 298 1.40 558 -15.84 0.0002
2022-02-14 2021-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 21,346 108 0.51 663 28.74 0.0002
2021-11-15 2021-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 21,238 10,816 103.78 515 238.82 0.0002
2021-08-12 2021-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 10,422 -1,191 -10.26 152 -47.59 0.0001
2021-05-17 2021-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 11,613 1,718 17.36 290 7.41 0.0001
2021-02-12 2020-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 9,895 -86 -0.86 270 46.74 0.0001
2020-11-13 2020-09-30 13F RETROPHIN COM 761299106 9,981 -66 -0.66 184 -10.24 0.0001
2020-08-14 2020-06-30 13F RETROPHIN COM 761299106 10,047 227 2.31 205 43.36 0.0001
2020-05-14 2020-03-31 13F RETROPHIN COM 761299106 9,820 -24,378 -71.28 143 -70.58 0.0001
2020-02-13 2019-12-31 13F RETROPHIN COM 761299106 34,198 14,565 74.19 486 23.35 0.0002
2019-08-14 2019-06-30 13F RETROPHIN COM 761299106 19,633 1,109 5.99 394 -5.97 0.0002
2019-05-15 2019-03-31 13F RETROPHIN COM 761299106 18,524 2,658 16.75 419 16.39 0.0002
2019-02-15 2018-12-31 13F RETROPHIN COM 761299106 15,866 2,325 17.17 360 -7.46 0.0003
2018-11-20 2018-09-30 13F RETROPHIN COM 761299106 13,541 3,395 33.46 389 40.43 0.0003
2018-08-10 2018-06-30 13F RETROPHIN COM 761299106 10,146 -807 -7.37 277 13.06 0.0002
2018-05-17 2018-03-31 13F RETROPHIN COM 761299106 10,953 902 8.97 245 14.49 0.0002
2018-02-13 2017-12-31 13F RETROPHIN COM 761299106 10,051 0 0.00 214 -14.40 0.0002
2017-11-09 2017-09-30 13F RETROPHIN COM 761299106 10,051 1,387 16.01 250 48.81 0.0002
2017-08-03 2017-06-30 13F RETROPHIN COM 761299106 8,664 355 4.27 168 10.53 0.0001
2017-05-12 2017-03-31 13F RETROPHIN COM 761299106 8,309 -133 -1.58 152 -5.59 0.0001
2017-02-13 2016-12-31 13F RETROPHIN COM 761299106 8,442 3,825 82.85 161 59.41 0.0002
2016-10-12 2016-09-30 13F RETROPHIN COM 761299106 4,617 -1,728 -27.23 101 -9.82 0.0001
2016-08-16 2016-06-30 13F RETROPHIN COM 761299106 6,345 0 0.00 112 30.23 0.0001
2016-05-16 2016-03-31 13F RETROPHIN COM 761299106 6,345 1,867 41.69 86 -2.27 0.0001
2016-02-16 2015-12-31 13F RETROPHIN COM 761299106 4,478 0 0.00 88 2.33 0.0001
2015-11-13 2015-09-30 13F RETROPHIN COM 761299106 4,478 479 11.98 86 -33.85 0.0001
2015-07-31 2015-06-30 13F RETROPHIN COM 761299106 3,999 0 0.00 130 36.84 0.0002
2015-05-14 2015-03-31 13F RETROPHIN COM 761299106 3,999 0 0.00 95 97.92 0.0001
2015-02-20 2014-12-31 13F/A-1 RETROPHIN COM 761299106 3,999 0 0.00 48 26.32 0.0001
2015-02-17 2014-12-31 13F RETROPHIN COM 761299106 3,999 0 48 0.0001
2014-11-14 2014-09-30 13F RETROPHIN COM 761299106 3,999 3,999 38 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.